Cohance Lifesciences Limited — Itraconazole Exporter Profile
Indian Pharmaceutical Exporter · #1 for Itraconazole · $3.5M export value · DGFT Verified
Cohance Lifesciences Limited is the #1 Indian exporter of Itraconazole with $3.5M in export value and 69 verified shipments. Cohance Lifesciences Limited holds a 12.6% market share in Itraconazole exports across 5 countries. The company exports 4 pharmaceutical products worth $13.6M across 4 therapeutic categories.
Cohance Lifesciences Limited — Itraconazole Export Profile: Buyers & Destinations
Where Does Cohance Lifesciences Limited Export Itraconazole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $818.1K | 20 | 34.7% |
| AUSTRALIA | $471.8K | 16 | 20.0% |
| INDONESIA | $409.2K | 14 | 17.4% |
| CANADA | $347.3K | 10 | 14.7% |
| EGYPT | $309.5K | 9 | 13.1% |
Cohance Lifesciences Limited exports Itraconazole to 5 countries. The largest destination is BRAZIL accounting for 34.7% of Cohance Lifesciences Limited's Itraconazole shipments, followed by AUSTRALIA (20.0%) and INDONESIA (17.4%). These destinations reflect Cohance Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Itraconazole from Cohance Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NOVAMED FABRICACAO DE PRODUTOS | BRAZIL | $517.9K | 13 |
| MINT PHARMACEUTICALS INC | CANADA | $247.3K | 8 |
| ARROW PHARMACEUTICALS PTY LTD | AUSTRALIA | $246.6K | 9 |
| ARROW PHARMACEUTICALS PTY LIMITED | AUSTRALIA | $225.1K | 7 |
| NOVAMED FABRICACAO DE PRODUCTOS | BRAZIL | $200.0K | 4 |
| PT DEXA MEDICA | INDONESIA | $200.0K | 4 |
| QNB ALAHLI BANK | EGYPT | $179.7K | 6 |
| TO THE ORDER OF | INDONESIA | $133.8K | 3 |
| QNB ALAHLI | EGYPT | $89.9K | 2 |
| PT.INTERBAT | INDONESIA | $67.9K | 2 |
Cohance Lifesciences Limited supplies Itraconazole to 18 buyers globally. The largest buyer is NOVAMED FABRICACAO DE PRODUTOS (BRAZIL), followed by MINT PHARMACEUTICALS INC (CANADA) and ARROW PHARMACEUTICALS PTY LTD (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Itraconazole Export Value and How Much Does Cohance Lifesciences Limited Contribute?
India exported $17.8M worth of Itraconazole through 2,727 shipments from 285 suppliers to 123 countries, serving 629 buyers globally. Cohance Lifesciences Limited contributes $3.5M to this total, accounting for 12.6% of India's Itraconazole exports. Cohance Lifesciences Limited ships Itraconazole to 5 countries through 18 buyers.
What Is the Average Shipment Value for Cohance Lifesciences Limited's Itraconazole Exports?
Cohance Lifesciences Limited's average Itraconazole shipment value is $50.0K per consignment, based on 69 shipments totaling $3.5M. The largest destination is BRAZIL (34.7% of Cohance Lifesciences Limited's Itraconazole exports).
How Does Cohance Lifesciences Limited Compare to Other Indian Itraconazole Exporters?
Cohance Lifesciences Limited ranks #1 among 285 Indian Itraconazole exporters with a 12.6% market share. The top 3 exporters are COHANCE LIFESCIENCES LIMITED ($3.5M), MICRO LABS LIMITED ($2.6M), AMNEAL PHARMACEUTICALS PRIVATE LIMITED ($1.9M). Cohance Lifesciences Limited processed 69 shipments to 5 destination countries.
What Itraconazole Formulations Does Cohance Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ITRACONAZOLE IR PELLETS 22% | $435.4K | 13 |
| ITRACONAZOLE IR PELLETS 21.74% | $275.4K | 11 |
| ITRACONAZOLE CAPSULES 100MG | $212.9K | 5 |
| ITRACONAZOLE IR PELLETS 22% W/W | $200.0K | 4 |
| ITRACONAZOLE IR PELLETS 22%KGS | $199.4K | 4 |
| COMMERCIAL INVOICE NO IN3600000533 DT 16 03 2023 ACTIVE PHARMACEUTICAL INGREDIENTS ITRACONAZOLE IR PELLETS 21 74 | $100.0K | 2 |
| ITRACONAZOLE IR PELLETS 22 | $97.3K | 3 |
| ITRACONAZOLE CAPSULES 100MG (30 CAPSULES)(QTY-13530) | $74.4K | 3 |
| ITRACONAZOLE CAPSULES 100MG (30 CAPSULES) (QTY:13260)NOS | $72.9K | 3 |
| TAX INV NO IN3600000501 DT 28 02 2023 PHARMACEUTICAL PRODUCT ITRACONAZOLE CAPSULES 100MG QTY 12983 | $50.0K | 1 |
Cohance Lifesciences Limited exports 30 distinct Itraconazole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ITRACONAZOLE IR PELLETS 22% with 13 shipments worth $435.4K.
Regulatory Requirements: Exporting Itraconazole to Key Markets
What Cohance Lifesciences Limited must comply with to export Itraconazole to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cohance Lifesciences Limited Compare to Nearest Itraconazole Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | COHANCE LIFESCIENCES LIMITED ★ | $3.5M | 69 | 5 | $50.0K |
| 4 | MICRO LABS LIMITED | $2.6M | 128 | 11 | $20.3K |
| 6 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $1.9M | 38 | 1 | $50.0K |
Cohance Lifesciences Limited ranks #1 among 285 Indian Itraconazole exporters. Average shipment value of $50.0K compared to the market average of $62.6K. The closest competitors by value are MICRO LABS LIMITED and AMNEAL PHARMACEUTICALS PRIVATE LIMITED.
Which Indian Ports Ship Itraconazole Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 498 | 18.3% |
| DELHI AIR CARGO ACC (INDEL4) | 415 | 15.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 345 | 12.7% |
| DELHI AIR | 245 | 9.0% |
| NHAVA SHEVA SEA (INNSA1) | 119 | 4.4% |
| Bombay Air | 98 | 3.6% |
| Delhi Air | 72 | 2.6% |
| JNPT/ NHAVA SHEVA SEA | 56 | 2.1% |
Geopolitical & Trade Policy Impact on Cohance Lifesciences Limited's Itraconazole Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Cohance Lifesciences. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and shipping costs. This situation necessitates strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost efficiency.
Conversely, the U.S.-China trade tensions have opened avenues for Indian exporters to capture market share previously dominated by Chinese manufacturers. Cohance's established presence and compliance with international standards position it favorably to meet the increased demand from U.S. importers seeking reliable alternatives.
The recent India-European Union Free Trade Agreement (FTA), concluded on January 27, 2026, eliminates tariffs on Indian pharmaceutical exports to the EU, including duties of up to 11% on pharmaceuticals. This development enhances Cohance's competitiveness in the European market, potentially boosting export volumes and revenues. (en.wikipedia.org)
Cohance Lifesciences Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for pharmaceutical exporters. The USFDA's issuance of a warning letter to Cohance's Hyderabad facility highlights the critical importance of adhering to Good Manufacturing Practices (GMP). While the immediate financial impact may be minimal due to the facility's limited contribution to U.S. revenues, the long-term implications on reputation and market access are significant. Proactive remediation and transparent communication with regulatory bodies are essential to restore and maintain compliance.
Additionally, the European Union's Falsified Medicines Directive (FMD) imposes stringent requirements on pharmaceutical imports. Cohance must ensure robust serialization and traceability measures to comply with these regulations, thereby safeguarding its access to the lucrative EU market.
About Cohance Lifesciences Limited
Cohance Lifesciences Limited exports 4 products worth $13.6M. Beyond Itraconazole, top products include Isosorbide, Spironolactone, Tetracycline. View the complete Cohance Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Itraconazole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Itraconazole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cohance Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 69 individual customs records matching Cohance Lifesciences Limited exporting Itraconazole, covering 30 formulations to 5 countries via 18 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 123+ countries, 629+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Itraconazole Export Data from Cohance Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cohance Lifesciences Limited's Itraconazole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cohance Lifesciences Limited
Full Company Profile →
4 products · $13.6M total trade · 4 categories
Itraconazole Stats
Company Overview
Top Products by Cohance Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cohance Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Itraconazole. For current shipment-level data, contact TransData Nexus.